PeptideCRO.com

A CRO, defined by the rule that governs it

In United States drug law a contract research organization is "a person that assumes, as an independent contractor with the sponsor, one or more of the obligations of a sponsor".1 A sponsor may hand over any or all of those obligations in writing, and a CRO that accepts one "shall be subject to the same regulatory action as a sponsor" for it.2

In practice a peptide CRO takes on the peptide-specific parts of a program: building sequences, purifying them, proving what is in the vial and often the assay work that follows. A provider that also manufactures under good manufacturing practice is called a CDMO. The FDA's guidance on quality agreements expects a written agreement stating which party carries out each CGMP activity, with both responsible for compliance.3

Solid-phase synthesis, the core service

Most peptides are made by solid-phase peptide synthesis, the method Bruce Merrifield published in 1963 with a tetrapeptide built on a polymer bead,4 and for which he received the 1984 Nobel Prize in Chemistry "for his development of methodology for chemical synthesis on a solid matrix".5 The chain grows one protected amino acid at a time on a resin, through repeated cycles of deprotection, washing, coupling and capping, until a final cleavage step releases it.6 Fmoc chemistry is "the method of choice", its building blocks made economical by the multiton production of therapeutic peptides.7

Purification and analytical characterisation

The crude product carries peptide-related impurities that share its sequence: deletions, insertions, truncated chains, wrong enantiomers or diastereomers and residual protecting groups.6 Preparative reversed-phase HPLC removes most of them; the analytical package proves what remains. The EMA guideline lists what a specification covers: identity, purity and related impurities, assay, amino acid analysis, counter-ion, water, residual solvents and endotoxins.6 Synthetic peptides are excluded from ICH Q3A, so the European Pharmacopoeia sets peptide-specific thresholds: reported above 0.1%, identified above 0.5% and qualified above 1.0%.6 Stability studies follow the ICH stability guidelines, with peptide-specific degradation routes such as oxidation, deamidation and aspartimide formation.6

Research grade or GMP

The same sequence can be ordered at two levels. Research-grade material serves assays and preclinical work. GMP material supports clinical trials and supply, made under ICH Q7, the good-manufacturing-practice guide for active pharmaceutical ingredients,8 and, for finished products in the United States, 21 CFR Parts 210 and 211.3 Under GMP the protected amino acid derivatives are starting materials with their own specifications, because an impurity in a building block can be written into the sequence.6 A peptide CRO sells that distinction: the same molecule, a different weight of documentation.

From discovery to IND: how peptide drugs are developed

Peptides sit "at the interface of small molecules and proteins".6 The FDA treats a polymer of 40 or fewer amino acids as a peptide, regulated as a drug, and its 2023 draft guidance notes that proteolytic degradation is rapid and that hepatic metabolism rarely matters for clearance,9 which is why half-life is the field's central engineering problem.

Discovery begins with libraries: phage display, first reported in 1985 and recognised with the 2018 Nobel Prize in Chemistry,10 and mRNA display for macrocycles with unnatural residues.11 Chemistry then buys time in the body. Fatty-acid derivatization, or lipidation, first applied to insulin, protracts action through albumin binding.12 PEGylation raises effective molecular weight to slow renal clearance.11 Cyclisation improves proteolytic stability, and more than 40 cyclic peptide drugs are in clinical use.13 Stapled peptides cross-link residues to hold an α-helix in shape.11

The GLP-1 class is the visible example. The FDA label of a once-weekly GLP-1 receptor agonist approved in 2017 describes 94% sequence homology to human GLP-1, a C18 fatty di-acid on lysine 26 for albumin binding, a change at position 8 against DPP-4 degradation and an elimination half-life of about one week.14 Since insulin, more than 80 peptide drugs have reached the market.15 Every step above is work a sponsor can place with a peptide CRO, from library synthesis to GMP batches for the IND.

The regulatory context in 2026

EMA's Guideline on the Development and Manufacture of Synthetic Peptides, adopted in December 2025, came into effect on 1 June 2026, covering process, characterisation and specifications.6 On 28 July 2026 the FDA published 17 revised draft product-specific guidances for generic peptide products across five areas: submission of recombinantly, synthetically or semi-synthetically produced peptides as ANDAs, innate immune response testing, impurity thresholds, higher order structure and biological activity. The same day it withdrew its 2021 guidance on synthetic peptides that refer to rDNA-origin drugs.16 Both put impurity identification and immunogenicity assessment, a peptide CRO's daily work, at the centre.

Who buys a name like PeptideCRO.com

Likely buyers:

• Peptide CROs and CDMOs offering synthesis, analytics and GMP supply under one roof.
• Peptide synthesis CROs and catalogue suppliers whose order book is research-grade sequences and libraries.
• Analytical laboratories specialising in peptide impurities, stability and immunogenicity risk.
• Discovery partners running display libraries, analogue design and half-life extension chemistry.
• Procurement platforms and marketplaces that route sequences to qualified labs.

Regulators write contract research organization; the trade says peptide CRO, peptide synthesis CRO or CDMO. PeptideCRO.com is the short form sponsors type.

1. 21 CFR 312.3, Definitions: contract research organization.eCFR
2. 21 CFR 312.52, Transfer of obligations to a contract research organization.eCFR
3. Contract Manufacturing Arrangements for Drugs: Quality Agreements.FDA guidance, November 2016
4. Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide.Journal of the American Chemical Society, 1963
5. The Nobel Prize in Chemistry 1984.NobelPrize.org
6. Guideline on the Development and Manufacture of Synthetic Peptides.European Medicines Agency, in effect 1 June 2026
7. Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis.Journal of Peptide Science, 2016
8. ICH Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.ICH, 2000
9. Clinical Pharmacology Considerations for Peptide Drug Products.FDA draft guidance, December 2023
10. The Nobel Prize in Chemistry 2018.NobelPrize.org
11. Wang L et al. Therapeutic peptides: current applications and future directions.Signal Transduction and Targeted Therapy, 2022
12. Kurtzhals P et al. Derivatization with fatty acids in peptide and protein drug discovery.Nature Reviews Drug Discovery, 2023
13. Zorzi A, Deyle K, Heinis C. Cyclic peptide therapeutics: past, present and future.Current Opinion in Chemical Biology, 2017
14. Prescribing information, semaglutide injection (GLP-1 receptor agonist), NDA 209637.FDA, 2017
15. Muttenthaler M et al. Trends in peptide drug discovery.Nature Reviews Drug Discovery, 2021
16. Revised Draft Product-Specific Guidances for Certain Generic Peptide Products.FDA, 28 July 2026